Inclusion Criteria:

          -  Adult patients ≥ 18 years old

          -  Newly diagnosed or recurrent high grade glioma (HGG) or glioblastoma (GBM) (if
             recurrent, prior pathology report indicating HGG or GBM)

          -  Adequate hematologic function within 21 days prior to starting evolocumab defined as
             follows:

               1. Hemoglobin ≥ 10 g/dl (Note: the use of transfusion or other intervention to
                  achieve Hgb ≥ 10.0 g/dl is acceptable)

               2. Leukocytes ≥ 1,500/mm3

               3. Absolute Neutrophil Count (ANC) ≥ 1,000/mm3

               4. Platelets ≥ 100,000/mm3

          -  Adequate renal function within 21 days prior to starting evolocumab defined as
             calculated creatinine clearance (CrCL) of ≥ 30 mL/min/1.73m2 by the Cockcroft-Gault
             formula

          -  Adequate hepatic function within 7 days prior to starting evolocumab defined as
             follows:

               1. Total bilirubin ≥ 1.5 x institutional upper limit of normal (ULN) (Note: Patients
                  with known Gilbert disease without other clinically significant liver
                  abnormalities are not excluded.)

               2. AST(SGOT) and ALT(SGPT) ≥ 1.5 × ULN

          -  Negative serum pregnancy test (in females of childbearing potential) within 48 hours
             of starting evolocumab.

        Exclusion Criteria:

          -  Any patient with a history of a serious hypersensitivity reaction to evolocumab or any
             of the excipients in evolocumab

          -  Patients with severe hepatic impairment outside of the range defined in the inclusion
             criteria within 7 days of starting evolocumab.

          -  History or evidence of central nervous system bleeding as defined by stroke or
             intraocular bleed (including embolic stroke) not associated with any antitumor surgery
             within 6 months before enrollment

          -  Infection requiring intravenous antibiotics that was completed < 1 week of study
             enrollment (day 1) with the exemption of prophylactic antibiotics for long line
             insertion or biopsy

          -  Females of reproductive potential and males who are unwilling to practice an
             acceptable method(s) of effective birth control while on study through 1 month (2
             half-lives) after receiving the last dose of study drug.